Some pharmaceutical products have become massively popular in the past few years. The class of vaccines and drugs that help prevent and treat COVID-19 is a good example. These allowed us to contain the pandemic, so their fame is well deserved. Another category of drugs has been making plenty of noise lately: anti-obesity medicines.Perhaps the most famous is Wegovy, marketed by Novo Nordisk (NVO -1.64%). The Denmark-based drugmaker is a leader in this niche. Though Wegovy still has a long and bright future a ...

In this articleNVONOVO.B-DKVictoria Klesty | ReutersIn the U.S., Wegovy is no longer just for weight loss.The blockbuster drug — one of a handful of weight loss treatments to skyrocket in popularity over the last year — is now approved in the U.S. for heart health, too. But that may not translate to wider insurance coverage of the weekly injection drug from Novo Nordisk and similar obesity treatments just yet.Some employers and other health plans are still reluctant to cover Wegovy due to its hefty $1,350 m ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Sc ...

Danish pharmaceutical company Novo Nordisk (NVO -1.37%) has taken the world by storm thanks to its popular diabetes and obesity medications Ozempic, Rybelsus, and Wegovy.2023 was a milestone year for Novo Nordisk, with Ozempic and Wegovy playing lead roles in the company's growth. Just last week, Novo Nordisk received some positive news from the Food and Drug Administration (FDA), and the shares soared to new highs.Let's break down what's going on at Novo Nordisk and assess why the company's best days may b ...

A big focus for healthcare companies recently has been on the weight-loss industry. It's no coincidence that two of the most valuable healthcare stocks in the world are big players in that field with a couple of promising weight-loss treatments.Companies are eager to get glucagon-like peptide 1 (GLP-1) drugs to market because they could help bolster their long-term growth prospects. And investors are paying attention, as possessing the next big weight-loss drug could be a sign of a stock that's due to skyro ...

Who is better, the United States of America or the European Union? On the one hand, European citizens are by and large privy to free access to healthcare, though the land of the free is considerably less stingy with its food portion sizes. The benefits of each can be argued until the cows come home, but what about stock market performance? Deutsche Bank analysts have dug deep into the data to provide some enlightening comparisons between Europe’s ‘Fabulous 5’ big-cap stocks and the US’s ‘Magnificent 7’. You ...

One of the healthcare stocks of the moment, Novo Nordisk (NVO 2.95%), had a good Tuesday on the market. Investors pushed its price 3% higher, more than double the percentage rate increase of the S&P 500 index, on the back of a positive move by an analyst.Included on the Argus focus listThat action occurred late Monday afternoon, when Argus Research director Jim Kelleher added Novo Nordisk to his company's focus list. It made the lineup along with three other stocks: Domino's Pizza, Shell, and Capital One Fi ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

Core Viewpoint - Novo Nordisk has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimate Revisions - The Zacks Consensus Estimate for Novo Nordisk projects earnings of $3.36 per share for the fiscal year ending December 2024, reflecting a year-over-year increase of 24.4% [5]. - Over the past three months, analysts have raised their earnings estimates for Novo Nordisk by 6.9% [5]. Impact of Institutional Investors - Changes in earnings estimates are strongly correlated with stock price movements, as institutional investors adjust their valuations based on these estimates, leading to buying or selling actions that affect stock prices [3]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [4]. - Novo Nordisk's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for price appreciation in the near term [7].

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Novo Nordisk (NVO) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Novo Nordisk currently has an ...